Inhibitors of erk and methods of use
AssigneeKura Oncology, Inc.
InventorsLiansheng LI, Tao Wu, Jun FENG, Pingda REN, Yi LIU
Life of this patent
Estimating the term…
Abstract
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
Claims64
A compound of Formula I:
- or a pharmaceutically acceptable salt or prodrug thereof;
- wherein:
- is
- X1 is C═O, C═S, SO, SO2, or PO2−;
- Y is CR5;
- W is N or C;
- X2 is NR1 or CR1R1′ and X3 is a bond, CR3R3′ or C═O;
- or X2—X3 is R11C═CR3 or R11C═N or N═CR3 or NR12—CR11═CR3;
- X4 is N, CR4, C═O;
- X5 is N or C;
- X6 is N or C;
- X7 is O, N, NR72 or CR71;
- X8 is O, N, NR82 or CR81;
- X9 is O, N, NR22 or CR21;
- X10 is O, N, NR92 or CR91;
- R1 is —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —C1-10alkyl-C3-10aryl, —C1-10alkyl-C1-10hetaryl, —C1-10alkyl-C3-10cycloalkyl, —C1-10alkyl-C1-10heterocyclyl, —C2-10alkenyl-C3-10aryl, —C2-10alkenyl-C1-10hetaryl, —C2-10alkenyl-C3-10cycloalkyl, —C2-10alkenyl-C1-10heterocyclyl, —C2-10alkynyl-C3-10aryl, —C2-10alkynyl-C1-10hetaryl, —C2-10alkynyl-C3-10cycloalkyl, —C2-10alkynyl-C1-10heterocyclyl, —C1-10alkoxy-C3-10aryl, —C1-10alkoxy-C1-10hetaryl, —C1-10alkoxy-C3-10cycloalkyl, —C1-10alkoxy-C1-10heterocyclyl, —C1-10heteroalkyl-C3-10aryl, —C1-10heteroalkyl-C1-10hetaryl, —C1-10heteroalkyl-C3-10cycloalkyl, —C1-10heteroalkyl-C1-10heterocyclyl, —C3-10aryl-C1-10alkyl, —C3-10aryl-C2-10alkenyl, —C3-10aryl-C2-10alkynyl, —C3-10aryl-C3-10hetaryl, —C3-10aryl-C3-10cycloalkyl, —C3-10aryl-C1-10heterocyclyl, —C1-10hetaryl-C1-10alkyl, —C1-10hetaryl-C2-10alkenyl, —C1-10hetaryl-C2-10alkynyl, —C3-10hetaryl-C3-10aryl, —C1-10hetaryl-C3-10cycloalkyl, —C1-10hetaryl-C1-10heterocyclyl, —C3-10cycloalkyl-C1-10alkyl, —C3-10cycloalkyl-C2-10alkenyl, —C3-10cycloalkyl-C2-10alkynyl, —C3-10cycloalkyl-C3-10aryl, —C3-10cycloalkyl-C1-10hetaryl, —C3-10cycloalkyl-C1-10heterocyclyl, —C1-10heterocyclyl-C1-10alkyl, —C1-10heterocyclyl-C2-10alkenyl, —C1-10heterocyclyl-C2-10alkynyl, —C1-10heterocyclyl-C3-10aryl, —C1-10heterocyclyl-C1-10hetaryl, or —C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R10 or R11 substituents;
- R1′ is hydrogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —C1-10alkyl-C3-10aryl, —C1-10alkyl-C1-10hetaryl, —C1-10alkyl-C3-10cycloalkyl, —C1-10alkyl-C1-10heterocyclyl, —C2-10alkenyl-C3-10aryl, —C2-10alkenyl-C1-10hetaryl, —C2-10alkenyl-C3-10cycloalkyl, —C2-10alkenyl-C1-10heterocyclyl, —C2-10alkynyl-C3-10aryl, —C2-10alkynyl-C1-10hetaryl, —C2-10alkynyl-C3-10cycloalkyl, —C2-10alkynyl-C1-10heterocyclyl, —C1-10alkoxy-C3-10aryl, —C1-10alkoxy-C1-10hetaryl, —C1-10alkoxy-C3-10cycloalkyl, —C1-10alkoxy-C1-10heterocyclyl, —C1-10heteroalkyl-C3-10aryl, —C1-10heteroalkyl-C1-10hetaryl, —C1-10heteroalkyl-C3-10cycloalkyl, —C1-10heteroalkyl-C1-10heterocyclyl, —C3-10aryl-C1-10alkyl, —C3-10aryl-C2-10alkenyl, —C3-10aryl-C2-10alkynyl, —C3-10aryl-C3-10hetaryl, —C3-10aryl-C3-10cycloalkyl, —C3-10aryl-C1-10heterocyclyl, —C1-10hetaryl-C1-10alkyl, —C1-10hetaryl-C2-10alkenyl, —C1-10hetaryl-C2-10alkynyl, —C3-10hetaryl-C3-10aryl, —C1-10hetaryl-C3-10cycloalkyl, —C1-10hetaryl-C1-10heterocyclyl, —C3-10cycloalkyl-C1-10alkyl, —C3-10cycloalkyl-C2-10alkenyl, —C3-10cycloalkyl-C2-10alkynyl, —C3-10cycloalkyl-C3-10aryl, —C3-10cycloalkyl-C1-10hetaryl, —C3-10cycloalkyl-C1-10heterocyclyl, —C1-10heterocyclyl-C1-10alkyl, —C1-10heterocyclyl-C2-10alkenyl, —C1-10heterocyclyl-C2-10alkynyl, —C1-10heterocyclyl-C3-10aryl, —C1-10heterocyclyl-C1-10hetaryl, or —C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R10 or R11 substituents;
- R21 is hydrogen, halogen, —OH, —CF3, —OCF3, —OR31, —NR31R32, —C(O)R31, —CO2R31, —C(═O)NR31, —NO2, —CN, —S(O)0-2R31, —SO2NR31R32, —NR31C(═O)R32, —NR31C(═O)OR32, —NR31C(═O)NR32R33, —NR31S(O)0-2R32, —C(═S)OR31, —C(═O)SR31, —NR31C(═NR32)NR32R33, —NR31C(═NR32)OR33, —NR31C(═NR32)SR33, —OC(═O)OR33, —OC(═O)NR31R32, —OC(═O)SR31, —SC(═O)SR31, —P(O)OR31OR32, —SC(═O)NR31R32, -L-C1-10alkyl, -L-C2-10alkenyl, -L-C2-10alkynyl, -L-C1-10heteroalkyl, -L-C3-10aryl, -L-C1-10hetaryl, -L-C3-10cycloalkyl, -L-C1-10heterocyclyl, -L-C1-10alkyl-C3-10aryl, -L-C1-10alkyl-C1-10hetaryl, -L-C1-10alkyl-C3-10cycloalkyl, -L-C1-10alkyl-C1-10heterocyclyl, -L-C2-10alkenyl-C3-10aryl, -L-C2-10alkenyl-C1-10hetaryl, -L-C2-10alkenyl-C3-10cycloalkyl, -L-C2-10alkenyl-C1-10heterocyclyl, -L-C2-10alkynyl-C3-10aryl, -L-C2-10alkynyl-C1-10hetaryl, -L-C2-10alkynyl-C3-10cycloalkyl, -L-C2-10alkynyl-C1-10heterocyclyl, -L-C1-10alkoxy-C3-10aryl, -L-C1-10alkoxy-C1-10hetaryl, -L-C1-10alkoxy-C3-10cycloalkyl, -L-C1-10alkoxy-C1-10heterocyclyl, -L-C1-10heteroalkyl-C3-10aryl, -L-C1-10heteroalkyl-C1-10hetaryl, -L-C1-10heteroalkyl-C3-10cycloalkyl, -L-C1-10heteroalkyl-C1-10heterocyclyl, -L-C3-10aryl-C1-10alkyl, -L-C3-10aryl-C2-10alkenyl, -L-C3-10aryl-C2-10alkynyl, -L-C3-10aryl-C1-10hetaryl, -L-C3-10aryl-C3-10cycloalkyl, -L-C3-10aryl-C1-10heterocyclyl, -L-C1-10hetaryl-C1-10alkyl, -L-C1-10hetaryl-C2-10alkenyl, -L-C1-10hetaryl-C2-10alkynyl, -L-C1-10hetaryl-C3-10aryl, -L-C1-10hetaryl-C3-10cycloalkyl, -L-C1-10hetaryl-C1-10heterocyclyl, -L-C3-10cycloalkyl-C1-10alkyl, -L-C3-10cycloalkyl-C2-10alkenyl, -L-C3-10cycloalkyl-C2-10alkynyl, -L-C3-10cycloalkyl-C3-10aryl, -L-C3-10cycloalkyl-C1-10hetaryl, -L-C3-10cycloalkyl-C1-10heterocyclyl, -L-C1-10heterocyclyl-C1-10alkyl, -L-C1-10heterocyclyl-C2-10alkenyl, -L-C1-10heterocyclyl-C2-10alkynyl, -L-C1-10heterocyclyl-C3-10aryl, -L-C1-10heterocyclyl-C1-10hetaryl, or -L-C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R12 substituents;
- R22 is hydrogen, —OH, —CF3, —C(O)R31, —CO2R31, —C(═O)NR31, —S(O)0-2R31, —C(═S)OR31, —C(═O)SR31, -L-C1-10alkyl, -L-C2-10alkenyl, -L-C2-10alkynyl, -L-C1-10heteroalkyl, -L-C3-10aryl, -L-C1-10hetaryl, -L-C3-10cycloalkyl, -L-C1-10heterocyclyl, -L-C1-10alkyl-C3-10aryl, -L-C1-10alkyl-C1-10hetaryl, -L-C1-10alkyl-C3-10cycloalkyl, -L-C1-10alkyl-C1-10heterocyclyl, -L-C2-10alkenyl-C3-10aryl, -L-C2-10alkenyl-C1-10hetaryl, -L-C2-10alkenyl-C3-10cycloalkyl, -L-C2-10alkenyl-C1-10heterocyclyl, -L-C2-10alkynyl-C3-10aryl, -L-C2-10alkynyl-C1-10hetaryl, -L-C2-10alkynyl-C3-10cycloalkyl, -L-C2-10alkynyl-C1-10heterocyclyl, -L-C1-10alkoxy-C3-10aryl, -L-C1-10alkoxy-C1-10hetaryl, -L-C1-10alkoxy-C3-10cycloalkyl, -L-C1-10alkoxy-C1-10heterocyclyl, -L-C1-10heteroalkyl-C3-10aryl, -L-C1-10heteroalkyl-C1-10hetaryl, -L-C1-10heteroalkyl-C3-10cycloalkyl, -L-C1-10heteroalkyl-C1-10heterocyclyl, -L-C3-10aryl-C1-10alkyl, -L-C3-10aryl-C2-10alkenyl, -L-C3-10aryl-C2-10alkynyl, -L-C3-10aryl-C1-10hetaryl, -L-C3-10aryl-C3-10cycloalkyl, -L-C3-10aryl-C1-10heterocyclyl, -L-C1-10hetaryl-C1-10alkyl, -L-C1-10hetaryl-C2-10alkenyl, -L-C1-10hetaryl-C2-10alkynyl, -L-C1-10hetaryl-C3 -10aryl, -L-C1-10hetaryl-C3 -10cycloalkyl, -L-C1-10hetaryl-C1-10heterocyclyl, -L-C3-10cycloalkyl-C1-10alkyl, -L-C3-10cycloalkyl-C2-10alkenyl, -L-C3-10cycloalkyl-C2-10alkynyl, -L-C3-10cycloalkyl-C3-10aryl, -L-C3-10cycloalkyl-C1-10hetaryl, -L-C3-10cycloalkyl-C1-10heterocyclyl, -L-C1-10heterocyclyl-C1-10alkyl, -L-C1-10heterocyclyl-C2-10alkenyl, -L-C1-10heterocyclyl-C2-10alkynyl, -L-C1-10heterocyclyl-C3-10aryl, -L-C1-10heterocyclyl-C1-10hetaryl, or -L-C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R12 substituents;
- L is a bond, —O—, —N(R31)—, —S(O)0-2—, —C(═O)—, —C(═O)O—, —OC(═O)—, —C(═O)N(R31)—, —N(R31)C(═O)—, —NR31C(═O)O—, —NR31C(═O)NR32—, —NR31S(O)0-2—, —S(O)0-2N(R31)—, —C(═S)O—, —C(═O)S—, —NR31C(═NR32)NR32—, —NR31C(═NR32)O—, —NR31C(═NR32)S—, —OC(═O)O—, —OC(═O)NR31—, —OC(═O)S—, —SC(═O)S—, —P(O)OR31O—, —SC(═O)NR31—;
- each of R3, R3′ and R4 is independently hydrogen, halogen, —OH, —CF3, —OCF3, —OR31, —NR31R32, —C(O)R31, —OO2R31, —C(═O)NR31, —NO2, —CN, —S(O)0-2R31, —SO2NR31R32, —NR31C(═O)R32, —NR31C(═O)OR32, —NR31C(═O)NR32R33, —NR31S(O)0-2R32, —C(═S)OR31, —C(═O)SR31, —NR31C(═NR32)NR32R33, —NR31C(═NR32)OR33, —NR31C(═NR32)SR33, —OC(═O)OR33, —OC(═O)NR31R32, —OC(═O)SR31, —SC(═O)SR31, —P(O)OR31OR32, —SC(═O)NR31R32, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —C1-10alkyl-C3-10aryl, —C1-10alkyl-C1-10hetaryl, —C1-10alkyl-C3-10cycloalkyl, —C1-10alkyl-C1-10heterocyclyl, —C2-10alkenyl-C3-10aryl, —C2-10alkenyl-C1-10hetaryl, —C2-10alkenyl-C3-10cycloalkyl, —C2-10alkenyl-C1-10heterocyclyl, —C2-10alkynyl-C3-10aryl, —C2-10alkynyl-C1-10hetaryl, —C2-10alkynyl-C3-10cycloalkyl, —C2-10alkynyl-C1-10heterocyclyl, —C1-10alkoxy-C3-10aryl, —C1-10alkoxy-C1-10hetaryl, —C1-10alkoxy-C3-10cycloalkyl, —C1-10alkoxy-C1-10heterocyclyl, —C1-10heteroalkyl-C3-10aryl, —C1-10heteroalkyl-C1-10hetaryl, —C1-10heteroalkyl-C3-10cycloalkyl, —C1-10heteroalkyl-C1-10heterocyclyl, —C3-10aryl-C1-10alkyl, —C3-10aryl-C2-10alkenyl, —C3-10aryl-C2-10alkynyl, —C3-10aryl-C3-10hetaryl, —C3-10aryl-C3-10cycloalkyl, —C3-10aryl-C1-10heterocyclyl, —C1-10hetaryl-C1-10alkyl, —C1-10hetaryl-C2-10alkenyl, —C1-10hetaryl-C2-10alkynyl, —C3-10hetaryl-C3-10aryl-C1-10hetaryl-C3-10cycloalkyl, —C1-10hetaryl-C1-10heterocyclyl, —C3-10cycloalkyl-C1-10alkyl, —C3-10cycloalkyl-C2-10alkenyl, —C3-10cycloalkyl-C2-10alkynyl, —C3-10cycloalkyl-C3-10aryl, —C3-10cycloalkyl-C1-10hetaryl, —C3-10cycloalkyl-C1-10heterocyclyl, —C1-10heterocyclyl-C1-10alkyl, —C1-10heterocyclyl-C2-10alkenyl, —C1-10heterocyclyl-C2-10alkynyl, —C1-10heterocyclyl-C3-10aryl, —C1-10heterocyclyl-C1-10hetaryl, or —C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R13 substituents;
- or R3′ is —OR6, —NR6R34, —S(O)0-2R6, —C (═O)R6, —C(═O)OR6, —OC(═O)R6, —C(═O)N(R34)R6, or —N(R34)C(═O)R6, wherein R6 together with R34 can optionally form a heterocyclic ring;
- each of R5, R71, R81 and R91 is independently hydrogen, halogen, —C1-10alkyl, —C2-10alkenyl, —C2-10 alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —OH, —CF3, —OCF3, —OR31, —NR31R32, —C(O)R31, —CO2R31, —C(═O)NR31, —NO2, —CN, —S(O)0-2R31, —SO2NR31R32, —NR31C(═O)R32, —NR31C(═O)OR32, —NR31C(═O)NR32R33, —NR31S(O)0-2R32, —C(═S)OR31, —C(═O)SR31, —NR31C(═NR32)NR32R33, —NR31C(═NR32)OR33, —NR31C(═NR32)SR33, —OC(═O)OR33, —OC(═O)NR31R32, —OC(═O)SR31, —SC(═O)SR31, —P(O)OR31OR32, or —SC(═O)NR31NR32;
- R6 is hydrogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —C1-10alkyl-C3-10aryl, —C1-10alkyl-C1-10hetaryl, —C1-10alkyl-C3-10cycloalkyl, —C1-10alkyl-C1-10heterocyclyl, —C2-10alkenyl-C3-10aryl, —C2-10alkenyl-C1-10hetaryl, —C2-10alkenyl-C3-10cycloalkyl, —C2-10alkenyl-C1-10heterocyclyl, —C2-10alkynyl-C3-10aryl, —C2-10alkynyl-C1-10hetaryl, —C2-10alkynyl-C3-10cycloalkyl, —C2-10alkynyl-C1-10heterocyclyl, —C1-10alkoxy-C3-10aryl, —C1-10alkoxy-C1-10hetaryl, —C1-10alkoxy-C3-10cycloalkyl, —C1-10alkoxy-C1-10heterocyclyl, —C1-10heteroalkyl-C3-10aryl, —C1-10heteroalkyl-C1-10hetaryl, —C1-10heteroalkyl-C3-10cycloalkyl, —C1-10heteroalkyl-C1-10heterocyclyl, —C3-10aryl-C1-10alkyl, —C3-10aryl-C2-10alkenyl, —C3-10aryl-C2-10alkynyl, —C3-10aryl-C3-10hetaryl, —C3-10aryl-C3-10cycloalkyl, —C3-10aryl-C1-10heterocyclyl, —C1-10hetaryl-C1-10alkyl, —C1-10hetaryl-C2-10alkenyl, —C1-10hetaryl-C2-10alkynyl, —C3-10hetaryl-C3-10aryl, —C1-10hetaryl-C3-10cycloalkyl, —C1-10hetaryl-C1-10heterocyclyl, —C3-10cycloalkyl-C1-10alkyl, —C3-10cycloalkyl-C2-10alkenyl, —C3-10cycloalkyl-C2-10 alkynyl, —C3-10cycloalkyl-C3-10aryl, —C3-10cycloalkyl-C1-10hetaryl, —C3-10cycloalkyl-C1-10heterocyclyl, —C1-10heterocyclyl-C1-10alkyl, —C1-10heterocyclyl-C2-10alkenyl, —C1-10heterocyclyl-C2-10alkynyl, —C1-10heterocyclyl-C3-10aryl, —C1-10heterocyclyl-C1-10hetaryl, or —C1-10heterocyclyl-C3-10cycloalkyl, each of which is unsubstituted or substituted by one or more independent R14 or R15 substituents;
- each of R72, R82 and R92 is independently hydrogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —OH, —CF3, —C(O)R31, —CO2R31, —C(═O)NR31, —S(O)0-2R31, —C(═S)OR31, —C(═O)SR31;
- each of R10 and R14 is —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, optionally substituted by one or more independent R11 substituents;
- each of R11, R12, R13 and R15 is independently hydrogen, halogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, —OH, —CF3, —OCF3, —OR31, —NR31R32, —C(O)R31, —CO2R31, —C(═O)NR31, —NO2, —CN, —S(O)0-2R31, —SO2NR31R32, —NR31C(═O)R32, —NR31C(═O)OR32, —NR31C(═O)NR32R33, —NR31S(O)0-2R32, —C(═S)OR31, —C(═O)SR31, —NR31C(═NR32)NR32R33, —NR31C(═NR32)OR33, —NR31C(═NR32)SR33, —OC(═O)OR33, —OC(═O)NR31R32, —OC(═O)SR31, —SC(═O)SR31, —P(O)OR31OR32, or —SC(═O)NR31NR32;
- each of R31, R32, R33 and R34 is independently hydrogen, halogen, —C1-10alkyl, —C2-10alkenyl, —C2-10alkynyl, —C1-10heteroalkyl, —C3-10aryl, —C1-10hetaryl, —C3-10cycloalkyl, —C1-10heterocyclyl, or wherein R31 together with R32 form a heterocyclic ring;
- wherein ring A comprises one or more heteroatoms selected from N, O, or S;
- and
- wherein if X7 is O or X2—X3 is R1C═CR3, ring A comprises at least two heteroatoms selected from N, O, or S;
- and
- wherein if X3 is O or N, or X2—X3 is R1C═N, at least one of X7 or X9 is not N.
The compound, pharmaceutically acceptable salt, or prodrug of any preceding claim, wherein R72 is H.
The compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims, wherein R5 is hydrogen.
The compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims, wherein X4 is CR4.
The compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims, wherein X4 is N.
The compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims, wherein X9 is CR21 or NR22, wherein R21 or R22 is halogen, —CN, -L-C3-10aryl, -L-C1-10hetaryl, -L-C3-10cycloalkyl, or -L-C1-10heterocyclyl, unsubstituted or substituted by one or more independent R12 substituents.
A method of inhibiting activity of a protein kinase present in a cell, comprising contacting said cell with an effective amount of a compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims.
A method of ameliorating a disorder comprising administering to a subject in need thereof an effective amount of a compound, pharmaceutically acceptable salt, or prodrug of a compound of any of the preceding claims, wherein the disorder is selected from the group consisting of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, and cardiac disease.
A pharmaceutical composition comprising the compound, pharmaceutically acceptable salt, or prodrug of any of the preceding claims and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.